Investors in Aardvark Therapeutics Could Join Class Action Over Alleged Securities Fraud

Shareholders of Aardvark Therapeutics Have a Chance to Lead Securities Fraud Lawsuit

In a recent announcement, Glancy Prongay Wolke & Rotter LLP has informed shareholders of Aardvark Therapeutics, Inc. (AARD) that they may have the opportunity to take the lead in a class action lawsuit concerning securities fraud. This arises from a series of allegations that have surfaced regarding the company’s disclosures to investors that could have misled shareholders, leading to significant financial losses.

The Allegations Against Aardvark Therapeutics

The class action complaint states that between February 10, 2025, and May 14, 2026, Aardvark Therapeutics’ management made materially false or misleading statements regarding its product, ARD-101. Specifically, it is claimed that the company failed to adequately disclose the true safety profile of ARD-101, which investors were led to believe was much safer than it is in reality. This lack of transparency raises serious concerns not only about the company's operations but also about its future prospects in clinical and commercial avenues.

The allegations further suggest that the company overstated the product's regulatory and market potential, which contributed to misleading public statements about its financial health and operational integrity. As these claims unfold, investors who feel they have been wronged are now presented with a distinct opportunity to step forward before the upcoming deadline.

Take Action: Become a Lead Plaintiff

For shareholders who have suffered losses linked to their investments in Aardvark, the window to act is limited. Investors interested in leading the class action must file their intention by October 13, 2026. Glancy Prongay Wolke & Rotter LLP stands ready to assist anyone wanting to pursue their legal rights to recover losses due to these alleged infractions. The law firm, known for its robust litigation involving securities fraud, can guide potential plaintiffs through the complexities of the legal process.

If you're considering becoming a lead plaintiff, it is advisable to engage with legal counsel to better understand your rights and the steps you need to take. Even if you opt not to take direct action, you still have the right to remain an absentee class member, which does not require you to participate directly but entitles you to any recovery achieved by the group if the case is successful.

Why Choose Glancy Prongay Wolke & Rotter LLP?

Glancy Prongay Wolke & Rotter LLP is a prominent national law firm recognized for its expertise in representing investors and consumers in complex class action cases. With decades of experience and a track record of success, the firm was acknowledged as one of Law360's Securities Groups of the Year. Furthermore, the firm ranked second in total investor recoveries in a report by Institutional Shareholder Services for the year 2025. Its lawyers have managed a plethora of lawsuits across various corporate misconduct realms, making them well-equipped to handle any challenges that may arise in this particular case.

The firm’s past successes have attracted considerable media attention, being featured in reputable publications such as The Wall Street Journal, Bloomberg, and Forbes. However, it is essential to remember that prior results do not guarantee similar outcomes in future cases, each being determined on its unique merits.

What Comes Next?

As the deadline approaches, shareholders who believe they have viable claims should consider reaching out to Glancy Prongay Wolke & Rotter LLP to learn more about their circumstances. Investors can contact the firm via phone or email to seek clarification on their legal standing and potential next steps. This lawsuit could represent a significant opportunity for shareholders to reclaim their losses while addressing the alleged misconduct of Aardvark Therapeutics.

Individuals can also visit the law firm’s website for additional resources and detailed information on how to proceed. Do not miss the opportunity to take a stand for your rights as an Aardvark Therapeutics investor; the clock is ticking.